Orient announced that Yangzhou Orient, a wholly-owned subsidiary, recently received the “Drug Supplement Application Approval Notice” for the composite packaging of estradiol tablets/estradiol didroprogesterone tablets approved by the State Drug Administration, and approved additional specifications: estradiol tablets contain 1 mg of estradiol and 10 mg of didroprogesterone, and issued the drug approval number H20269208.

Orient announced that Yangzhou Orient, a wholly-owned subsidiary, recently received the “Drug Supplement Application Approval Notice” for the composite packaging of estradiol tablets/estradiol didroprogesterone tablets approved by the State Drug Administration, and approved additional specifications: estradiol tablets contain 1 mg of estradiol and 10 mg of didroprogesterone, and issued the drug approval number H20269208.